
Trixeo is the first and only triple-combination therapy approved in the EU for patients 12 years and older, independent of exacerbation history

The approval was based on phase 3 trial results showing a 56% risk reduction in disease progression

The treatment is to protect children under two years of age from respiratory syncytial virus

Hypertension affects more than 1.4 billion people worldwide and many patients remain uncontrolled despite multiple therapies

In 2026, an estimated 22,720 people in the US will be diagnosed with AML

Taken at any time of the day, the oral GLP-1 is the only pill to have no food or water restrictions

The autoimmune disease affects approximately three to five million people globally

Approximately 70% of metastatic triple-negative breast cancer patients are ineligible for immunotherapy, creating an unmet medical need

The study demonstrated reduction in systolic blood pressure compared to placebo in patient with hypertension

Diabetes drug fails to show benefit over placebo